Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michihiro Hide

Showing results (241-250 of 287) with videos related to

Pageof 29
Sort By:
American Journal of Human Genetics|July 11, 2021
Genome-wide association study reveals an association between the HLA-DPB1<sup>∗</sup>02:01:02 allele and wheat-dependent exercise-induced anaphylaxisKoya Fukunaga, Yuko Chinuki, Yuto Hamada, et al.
The Journal of Dermatology|December 21, 2024
English version of clinical practice guidelines for the management of atopic dermatitis 2024Hidehisa Saeki, Yukihiro Ohya, Hirokazu Arakawa, et al.
American Journal of Clinical Dermatology|June 20, 2020
Dupilumab Provides Favorable Safety and Sustained Efficacy for up to 3 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic DermatitisLisa A Beck, Diamant Thaçi, Mette Deleuran, et al.
The Journal of Allergy and Clinical Immunology. in Practice|December 30, 2022
Epidemiology, Management, and Treatment Access of Hereditary Angioedema in the Asia Pacific Region: Outcomes From an International SurveyPhilip H Li, Ruby Pawankar, Bernard Yu-Hor Thong, et al.
Research Involvement and Engagement|February 2, 2021
The practice of active patient involvement in rare disease research using ICT: experiences and lessons from the RUDY JAPAN projectNao Hamakawa, Atsushi Kogetsu, Moeko Isono, et al.
Journal of Dermatological Science|April 4, 2017
Efficacy and safety of omalizumab in Japanese and Korean patients with refractory chronic spontaneous urticariaMichihiro Hide, Hae-Sim Park, Atsuyuki Igarashi, et al.
BMC Cancer|November 29, 2022
Prevalence of immune-related adverse events and anti-tumor efficacy following immune checkpoint inhibitor therapy in Japanese patients with various solid tumorsYuki Yoshikawa, Michio Imamura, Masami Yamauchi, et al.
Allergy|November 28, 2020
Oral berotralstat for the prophylaxis of hereditary angioedema attacks in patients in Japan: A phase 3 randomized trialIsao Ohsawa, Daisuke Honda, Yusuke Suzuki, et al.
Allergy|December 8, 2025
Long-Term Efficacy and Safety of Ligelizumab as Re-Treatment in Patients With Chronic Spontaneous UrticariaAna M Gimenez-Arnau, Marcus Maurer, Adam Reich, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology|January 12, 2025
Advocacy in Action: International Patient Group Improves Hereditary Angioedema Diagnosis and Care Across the Asia-PacificJane C Y Wong, Cheryl C W Tsui, Kristie C W Lao, et al.
Pageof 29

Showing results (241-250 of 287) with videos related to

Sort By:
Pageof 29
American Journal of Human Genetics|July 11, 2021
Genome-wide association study reveals an association between the HLA-DPB1<sup>∗</sup>02:01:02 allele and wheat-dependent exercise-induced anaphylaxisKoya Fukunaga, Yuko Chinuki, Yuto Hamada, et al.
The Journal of Dermatology|December 21, 2024
English version of clinical practice guidelines for the management of atopic dermatitis 2024Hidehisa Saeki, Yukihiro Ohya, Hirokazu Arakawa, et al.
American Journal of Clinical Dermatology|June 20, 2020
Dupilumab Provides Favorable Safety and Sustained Efficacy for up to 3 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic DermatitisLisa A Beck, Diamant Thaçi, Mette Deleuran, et al.
The Journal of Allergy and Clinical Immunology. in Practice|December 30, 2022
Epidemiology, Management, and Treatment Access of Hereditary Angioedema in the Asia Pacific Region: Outcomes From an International SurveyPhilip H Li, Ruby Pawankar, Bernard Yu-Hor Thong, et al.
Research Involvement and Engagement|February 2, 2021
The practice of active patient involvement in rare disease research using ICT: experiences and lessons from the RUDY JAPAN projectNao Hamakawa, Atsushi Kogetsu, Moeko Isono, et al.
Journal of Dermatological Science|April 4, 2017
Efficacy and safety of omalizumab in Japanese and Korean patients with refractory chronic spontaneous urticariaMichihiro Hide, Hae-Sim Park, Atsuyuki Igarashi, et al.
BMC Cancer|November 29, 2022
Prevalence of immune-related adverse events and anti-tumor efficacy following immune checkpoint inhibitor therapy in Japanese patients with various solid tumorsYuki Yoshikawa, Michio Imamura, Masami Yamauchi, et al.
Allergy|November 28, 2020
Oral berotralstat for the prophylaxis of hereditary angioedema attacks in patients in Japan: A phase 3 randomized trialIsao Ohsawa, Daisuke Honda, Yusuke Suzuki, et al.
Allergy|December 8, 2025
Long-Term Efficacy and Safety of Ligelizumab as Re-Treatment in Patients With Chronic Spontaneous UrticariaAna M Gimenez-Arnau, Marcus Maurer, Adam Reich, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology|January 12, 2025
Advocacy in Action: International Patient Group Improves Hereditary Angioedema Diagnosis and Care Across the Asia-PacificJane C Y Wong, Cheryl C W Tsui, Kristie C W Lao, et al.
Pageof 29